Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis
Federica Azzolini,
Luana Gilio,
Luigi Pavone,
Ennio Iezzi,
Ettore Dolcetti,
Antonio Bruno,
Fabio Buttari,
Alessandra Musella,
Georgia Mandolesi,
Livia Guadalupi,
Roberto Furlan,
Annamaria Finardi,
Teresa Micillo,
Fortunata Carbone,
Giuseppe Matarese,
Diego Centonze,
Mario Stampanoni Bassi
Affiliations
Federica Azzolini
IRCCS Neuromed, 86077 Pozzilli, Italy
Luana Gilio
IRCCS Neuromed, 86077 Pozzilli, Italy
Luigi Pavone
IRCCS Neuromed, 86077 Pozzilli, Italy
Ennio Iezzi
IRCCS Neuromed, 86077 Pozzilli, Italy
Ettore Dolcetti
IRCCS Neuromed, 86077 Pozzilli, Italy
Antonio Bruno
IRCCS Neuromed, 86077 Pozzilli, Italy
Fabio Buttari
IRCCS Neuromed, 86077 Pozzilli, Italy
Alessandra Musella
Synaptic Immunopathology Lab, IRCCS San Raffaele, 00163 Roma, Italy
Georgia Mandolesi
Synaptic Immunopathology Lab, IRCCS San Raffaele, 00163 Roma, Italy
Livia Guadalupi
Synaptic Immunopathology Lab, IRCCS San Raffaele, 00163 Roma, Italy
Roberto Furlan
Clinical Neuroimmunology Unit, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
Annamaria Finardi
Clinical Neuroimmunology Unit, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
Teresa Micillo
Neuroimmunology Unit, IRCCS Fondazione Santa Lucia, 00179 Rome, Italy
Fortunata Carbone
Neuroimmunology Unit, IRCCS Fondazione Santa Lucia, 00179 Rome, Italy
Giuseppe Matarese
Laboratory of Immunology, Institute of Endocrinology and Experimental Oncology, National Research Council, 80131 Naples, Italy
Background: Astrocytes and microglia play an important role in the inflammatory process of multiple sclerosis (MS). We investigated the associations between the cerebrospinal fluid (CSF) levels of glial fibrillary acid protein (GFAP) and soluble triggering receptors expressed on myeloid cells-2 (sTREM-2), inflammatory molecules, and clinical characteristics in a group of patients with relapsing-remitting MS (RRMS). Methods: Fifty-one RRMS patients participated in the study. Clinical evaluation and CSF collection were performed at the time of diagnosis. The CSF levels of GFAP, sTREM-2, and of a large set of inflammatory and anti-inflammatory molecules were determined. MRI structural measures (cortical thickness, T2 lesion load, cerebellar volume) were examined. Results: The CSF levels of GFAP and sTREM-2 showed significant correlations with inflammatory cytokines IL-8, G-CSF, and IL-5. Both GFAP and sTREM-2 CSF levels positively correlated with age at diagnosis. GFAP was also higher in male MS patients, and was associated with an increased risk of MS progression, as evidenced by higher BREMS at the onset. Finally, a negative association was found between GFAP CSF levels and cerebellar volume in RRMS at diagnosis. Conclusions: GFAP and sTREM-2 represent suitable biomarkers of central inflammation in MS. Our results suggest that enhanced CSF expression of GFAP may characterize patients with a higher risk of progression.